Antisense anti IGF-I cellular therapy of malignant tumours: Immune response in cancer patients

Biomedicine and Pharmacotherapy

Volumn 64, Issue 8, 2010, Pages 576-578

  Trojan, J ^a,b   Ly, A ^a,b   Wei, M X ^c   Bierwagen, M ^d   Kopinski, P ^d   Pan, Y ^b   Ardourel, M Y ^e   Dufour, T ^e   Shevelev, A ^f   Trojan, L A ^a,b   Francois J C ^g   Andres, C ^h   Popiela, T ⁱ   Chatel, M ^j   Kasprzak, H ^d   Anthony, D D ^b   Duc, H T ^a  

^a INSERM   (France)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cellvax   (France)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e UNIVERSITÉ D'ORLÉANS   (France)

^f MOSCOW STATE UNIVERSITY   (Russian Federation)

^g CNRS   (France)

^h CHU BRETONNEAU   (France)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^j Medical University   (France)

more..

Author keywords

Antisense therapy; Malignant tumours expressing IGF I; T CD8 immune effector phenotype

Indexed keywords

ANTINEOPLASTIC AGENT; CD28 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; SOMATOMEDIN C;

ANTISENSE THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED STUDY; EFFECTOR CELL; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77956880915     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.01.019     Document Type: Article

References (7)

1. Trojan J., Johnson T.R., Rudin S.D., Ilan J., Tykocinski M.L. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993, 259:94-97.
2. Trojan J., Johnson T.R., Rudin S.D., Blossey B.K., Kelley K.M., Shevelev A., et al. Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation. Proc Natl Acad Sci U S A 1994, 91:6088-6092.
3. Shevelev A., Burfeind P., Schulze E., Rininsland F., Johnson T.R., Trojan J., et al. Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model. Cancer Gene Ther 1997, 4:105-112.
4. Lafarge-Frayssinet C, Duc HT, Sarasin A et al. Antisense IGF-I transfer into rat hepatoma cell line inhibits tumorigenesis by modulating MHC-I. Cancer Gene Ther 1997;4:276-85.
5. Ellouk-Achard S., Djenabi S., De Oliveira G.A., et al. Induction of apoptosis in rat hepatoma cells by expression of IGF-I antisense cDNA. J Hepatology 1998, 29:807-818.
6. Trabado S., Nguyen Van Binh P., Martin C., Lafarge-Frayssinet C., Lone Y.C., et al. Stimulation anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9. Biomed Pharmacother 2007, 61:494-498.
7. Matlib M.A., Kihara M., Farrell C., Dage R.C. The Na+-Ca2+ exchange system in vascular smooth muscle cell membrane vesicles isolated from cultured cells and from tissue is similar. Biochim Biophys Acta 1988, 939:173-177.